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DOI 10.1016/j.str.2007.11.003By their very nature, science and tech-
nology change over time. The answers
to one question often lead to a host of
new questions, and as technology im-
proves we change not only how well
we can address specific problems but
even the types of problems we can
address. This is particularly true for bio-
medical research over thepast 50 years.
Recent advances have allowed us to
framequestions about evolutionandde-
velopment, and various types of molec-
ular networks within cells that were pre-
viously inaccessible with more limited
data collection and reductionist ap-
proaches. The change to large-scale
data acquisition for DNA sequencing
projects has been a productive one,
and while one needs to be careful about
changing for the sake of change, in gen-
eral change is good. Based on the suc-
cess of the genome projects, which
also met with considerable resistance
in the initial stages, a careful analysis
was conducted over 10 years ago by
NIGMS and NIH-funded researchers
that clearly highlighted a need for more
structural biology information than was
currently being generated. Furthermore,
the need for more structural data was
only going to increase with time. The
generation of one de novo structure ev-
ery 2–3 years by each structural biology
research group at an average cost in ex-
cessof 350Kper newstructurewas sim-
ply not sufficient or efficient given the
projected need.
High-Throughput Structural
Biology and Technology
Development
Lost in the Protein Structure Initiative
(PSI) debate are the advanced struc-
tural-biology-specific technologies that
have emerged. PSI-1 was primarily
about developing, evaluating, and nur-
turing the technologies to ascertain if
the rate of protein structure determina-tion and the efficiency of the process
could be increased and conducted in
a production-like format similar to the
genome projects. Thus, when one cal-
culates the overall cost of PSI, a signifi-
cant percentage was devoted to the
technologies that were delivered which
were of general use to all scientists,
fulfilling important requirements that
had not been previously addressed. In
PSI-2, there are six centers focused
on technology development, particu-
larly for the most challenging proteins
(e.g., membrane proteins, large and
transient complexes, and eukaryotic
proteins), and four centers focused on
production, which have technology
development components. Several of
the PSI-1 and PSI-2 technology high-
lights that emerged either directly or
indirectly include (complete list is avail-
able at http://cci.lbl.gov/kb-tech/):
 Improved cloning andexpression
tools specifically designed for
structural biology;
 Increased biophysical under-
standing of protein constructs
likely to crystallize, constructs
better suited for NMR analysis,
andwhich should not be pursued
in their current state;
 Reduction in sample volume/con-
centration requirements, particu-
larly for hard to express proteins
(e.g., membrane proteins/com-
plexes):
 Nanovolume crystallization, and
 Microcoil NMR;
 Crystallization and imaging ro-
botics;
 Automated 1D NMR screening of
samples (7 ml/20min per sample);
 Synchrotron automated crystal
sample changers;
 Improved NMR/X-ray data pro-
cessing/structure solution soft-
ware;Structure 15, December 2007 ª2 Data management systems to
evaluate both negative and
positive results that improve our
future experimental design;
 Improved metrics for structure
quality.
Of critical importance, the robust-
ness of the technologies have made
the determination of protein structure
more achievable by biochemists and
cell biologists and the cost of the
technologies have decreased to the
point that they are now becoming
commonplace. With miniaturization,
reagent cost also goes down (similar
to the change to microscale organic
synthesis decades ago). It is quite
likely that as more and more chemists
and biologists conduct routine molec-
ular biology in their own laboratories,
a similar situation will occur with
many protein structure projects being
determined by ‘‘non-structural biolo-
gists’’. This will probably bring shivers
to the traditional structural biologists
who have enjoyed publishing just
structures in high-profile journals, but
it is a positive direction for science
overall. A significant and different
perspective is provided by what an
enzymologist can see in the electron
density of the active site or what a
neurobiologist can see in the electron
density of a channel structure.
More Effective Training
of Students and Postdocs
Also lost inmuchof thedebateconcern-
ing PSI is the impact on postgraduate
education. One of the major drivers for
many of those involved in PSI-1 was
a frustration with the pace of obtaining
structural data, hit-or-miss successes,
and the repetitive nature of the existing
technologies. In evaluation of my lab
and other structural biology labs in
1995, I estimated that more than 60%007 Elsevier Ltd All rights reserved 1517
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ture determination projects was spent
conducting routine tasks repeatedly,
such as crystallization trials with differ-
ent constructs or purification proce-
dures, looking for crystals to mount in
the cold room, and then staying up for
24 hr straight at a synchrotron beamline
walking in one sample at a time. In the
case of de novo structure determina-
tions, this situation did not allow for the
majority of their time thinking about or
understanding the function andmecha-
nism of the beautiful structures they
uncovered. If today, students and post-
docs have to conduct structural biology
in strictly the ‘‘old-fashioned’’ way, then
this is indeed unfortunate for them. The
argument will be made that having stu-
dents and postdocs conduct research
in production centers is a robotic-like
task in itself, but the centers are very
sensitive to this. Technicians conduct
mostof the routine tasks,while students
and postdocs are encouraged to ana-
lyze and think about the information
being generated.
Impact
As with the Human Genome Project, it
is difficult to immediately appreciate
the impact of PSI on biomedical re-
search. As noted above, the technolo-
gies are key deliverables already in
place fromPSI. The integrationof these
technologies throughout the country
and the world is the strongest possible
endorsement of their critical need.
While PSI was getting started and in
the same spirit of PSI with analogous
approaches to drug discovery, several
high-throughput structure-based drug
discovery companies were formed.
These companies are all now maturing
and are starting to yield results from
their new ‘‘PSI-like’’ approaches to
drug discovery. Specifically, Syrrx
(now called Takeda San Diego) has
a Phase III drug for type 2 diabetes in
human clinical trials. SGX Pharmaceu-
ticals and Astex Therapeutics both
have drugs currently in Phase I and II
human clinical trials for oncology. Like-
wise, pharmaceutical companies now
value structural data so much that it is
considered critical data prior to enter-
ing clinical trials, an important change
in the last 5 years due in part to the
PSI related technologies.1518 Structure 15, December 2007 ª200An example of impact in the aca-
demic setting is the recent structure
of a human G protein coupled receptor
(GPCR; Cherezov et al., 2007; Rose-
nbaum et al., 2007). GPCRs are the
largest single family of proteins in the
human genome and the target of
more than 50% of all current marketed
drugs. The structure determination is
the result of the tireless pursuit of
GPCR structure by biochemist Brian
Kobilka at Stanford University coupled
to PSI technology developed in my
laboratory specifically for this particu-
lar family of receptors, namely minia-
turization and automation of novel
crystallization/imaging methods for
GPCRs. This collaborative effort re-
sulted in the long-awaited, high-reso-
lution structure of human b2 adrenergic
receptor. Obtaining the three-dimen-
sional structure of GPCRs has been
the pursuit of a large number of groups
around the world; both academia and
industry have invested millions and
millions of dollars into this single goal.
Although one can argue that the above
technologies and structures would
have eventually emerged, PSI in part-
nership with the NIH Roadmap Initia-
tive have accelerated all of this. Surely
most biologists would like structural
data on their newly discovered genes
sooner rather than later.
Protein Initiative-3 (or 1)
I am personally not excited about
solving structures with novel folds so
I am not a participant in a PSI-2 pro-
duction center. My interests are in
structural neurobiology and in devel-
oping critically needed technologies
that help myself and others accom-
plish their research goals. However, I
do appreciate the passion the PSI-2
production centers have for their
work and understand and appreciate
the big picture that will result from
their dedicated effort, as I also appre-
ciate the enormous efforts of those
working on viruses, ribosomes, and
other very challenging structural biol-
ogy projects. Once PSI-2 is com-
pleted in the summer of 2010, the
issue of how we will generate the
structural data that the scientific com-
munity needs will not go away. Protein
structures will continue to be critical
for the understanding of chemistry7 Elsevier Ltd All rights reservedand biology. Key considerations for
a Protein Initiative-3 (or 1) include:
 Careful re-evaluation of the tar-
gets/approaches for biomedical
research.
 Continuation of technology devel-
opment.This iscritical forstudying
the larger complexes and chal-
lenging proteins like those that ex-
ist in themembrane.Wealsoneed
increased production of these
very challenging protein struc-
tures so that we improve our fun-
damental understanding of these
key biological macromolecules.
 Function is as important as the
structures being generated and
this should become a more cen-
tral focus of any future program.
Already, movement is evident in
this area with chemical profiling
of protein families in a structural
genomics setting (Allali-Hassani
et al., 2007).
 Better coordination with other
proteomics approaches (e.g.,
activity-basedprofiling,metabolite
profiling of enzyme families, and
mass spectrometry differentiation
among various cellular species).
 Although we have seen X-ray and
NMR complement one another
better through PSI, electron mi-
croscopy has not been integrated
as well, in part due to the proteins
being studied. As we start to in-
vestigate larger complexes, the
membrane, and entire cells, elec-
tron microscopy and single mole-
cule analysis advanceswill be ex-
tremely important techniques to
integrate and further our under-
standing of biological structures
and their functions.
There is no question that certain
things could be done better in PSI, as
is often the case when change occurs.
What is important is thatwe havemade
tremendous strides in improving our
approaches to collect and understand
protein structures in the past several
years, and we are now in a better posi-
tion to keep up with the demand for
more structural data. I applaud NIGMS
staff for talking to scientific leaders
about current limitations and potential
new directions in the field, and for
Structure
Opinionstaking the initiative to change the way
we do science based on prior invest-
ments and new discoveries.
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Based on the success of genome se-
quencing projects and advances in
structural and computational biology,
in the late 1990s scientists fromseveral
countries proposed large-scale pro-
jects to map protein structure space.
The new field of structural genomics
was defined as the high-throughput
experimental determination of a large
number of representative structures,
with the goal of achieving systematic
sampling of sequence families. Utiliza-
tion of computational modeling of se-
quence family homologs would extend
the structural information to a much
larger fraction of sequenced genes.
One of the national efforts, the Protein
Structure Initiative (PSI), was estab-
lished in 2000 by the National Institute
of General Medical Sciences (NIGMS),
NIH, as one of the special initiatives es-
tablished during the NIH budget dou-
bling and after several national and
international workshops and extensive
consideration by the Institute staff
and the Institute’s Advisory Council.
The NIGMS held three workshops to
examine the feasibility, goals, scale,
and target selection strategy for a
structural genomics effort. Following
these workshops and staff discus-
sions, the Council concluded that the
Institute should undertake this effort
and asked the NIGMS staff to organize
a ‘‘pilot’’ phase of the PSI as a 5-year
project with the mission statement:
‘‘Tomake the three-dimensional atomicnau, P., Martin, F., Thornton, J., Edwards,
A.M., et al. (2007). Structural and chemical pro-
filing of the human cytosolic sulfotransferases.
PLoS Biol. 5, e97.
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B.K., et al. (2007). High-resolution crystal
structure of an engineered human b2-adrener-rotein Structure In
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level structures of most proteins easily
available from knowledge of their cor-
responding DNA sequences.’’
The First Phase of the Protein
Structure Initiative (PSI-1)
PSI-1 consisted of a centers program
and an investigator-initiated grants pro-
gram for methodology and technology
development. Nine pilot research cen-
ters were established to test strategies
for high-throughput structural determi-
nation. Two of these pilot centers were
cofunded by the NIH National Institute
of Allergy and Infectious Diseases
(NIAID). The goals of PSI-1 were to:
1. Develop methodology and tech-
nology to increase success
rates and lower costs of struc-
ture determination,
2. Construct and automate the
protein production and structure
determination pipeline, and
3. Determine novel protein struc-
tures. In this context, the term
‘‘novel’’ was defined to mean
structures for proteins that
were less than 30% identical in
sequence to proteins for which
structures had already been
determined.
During the first year, the Institute
appointed the Protein Structure Initia-
tive Advisory Committee (PSIAC), a
working group of the NIGMS Council
Structure 15, December 2007 ª2gic G protein-coupled receptor. Science 318,
1258–1265.
Rosenbaum, D.M., Cherezov, V., Hanson,
M.A., Rasmussen, S.G., Thian, F.S., Kobilka,
T.S., Choi, H.J., Yao, X.J., Weis, W.I., Stevens,
R.C., et al. (2007). GPCR engineering yields
high-resolution structural insights into b2
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composed of independent scientists
(i.e., not connected to the PSI), to pro-
vide strategic advice to the NIGMS
Council and staff on the management
and planning of the project. In formu-
lating this program, the intent was
explicitly not to compete with tradi-
tional high resolution structural biol-
ogy, but rather to generate a large
body of novel structural information
for use by the broad biomedical re-
search community.
Over the five years of PSI-1, the nine
pilot centers determined about 1300
structures of which approximately 65%
were novel (based on the 30% se-
quence identity criterion). Structures
contributed by PSI are comparable in
quality and size to structures de-
posited into the Protein Data Bank
(PDB) from other structural biology
laboratories. Since these centers took
several years to reach high-throughput
operation, it was not surprising that
40% of the PSI-1 structures were de-
termined in the fifth year of the project.
By this time, the cost per structure had
fallen more than 2-fold—to $138,000.
This estimated cost per structure in-
cludes funds for ongoing technology
development.
From this first phase of the PSI,
NIGMS staff and the PSIAC concluded
that several lessons had been learned:
 Structural genomicspipelinescan
be constructed and scaled up;
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